The economic value of a visceral leishmaniasis vaccine in Bihar State, India

American Journal of Tropical Medicine and Hygiene

Volumn 86, Issue 3, 2012, Pages 417-425

  Lee, Bruce Y ^a   Bacon, Kristina M ^a   Shah, Mirat ^a   Kitchen, Sarah Beth ^a   Connor, Diana L ^a   Slayton, Rachel B ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEISHMANIA VACCINE;

ARTICLE; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; INDIA; INFECTION RISK; VACCINATION; VISCERAL LEISHMANIASIS;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; ENDEMIC DISEASES; HEALTH CARE COSTS; HUMANS; INDIA; LEISHMANIA; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL;

EID: 84859565853     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2012.10-0415     Document Type: Article

References (51)

1. Hotez PJ, Ferris MT, 2006. The antipoverty vaccines. Vaccine 24: 5787-5799. (Pubitemid 43947393)
2. Vanlerberghe V, Diap G, Guerin PJ, Meheus F, Gerstl S, Van der Stuyft P, Boelaert M, 2007. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis. Trop Med Int Health 12: 274-283.
3. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD, 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76: 25-32. (Pubitemid 28254976)
4. Ahluwalia IB, Bern C, Costa C, Akter T, Chowdhury R, Ali M, Alam D, Kenah E, Amann J, Islam M, Wagatsuma Y, Haque R, Breiman RF, Maguire JH, 2003. Visceral leishmaniasis: consequences of a neglected disease in a Bangladeshi community. Am J Trop Med Hyg 69: 624-628. (Pubitemid 38248234)
5. Meheus F, Boelaert M, Baltussen R, Sundar S, 2006. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop Med Int Health 11: 1715-1724. (Pubitemid 44624375)
6. Joshi A, Prasittisuk C, Bhatia R, Hashim G, Jorge A, Banjara M, Kroeger A, 2008. Can visceral leishmaniasis be eliminated from Asia? J Vector Borne Dis 45: 105-111. (Pubitemid 351809286)
7. World Health Organization, 2007. WHO Special Programme for Research and Training in Tropical Diseases (TDR): research to support the elimination of visceral leishmaniasis. Geneva: WHO.
8. Berman J, 2009. ABLE: a new and improved amphotericin B for visceral leishmaniasis? Am J Trop Med Hyg 80: 689-690.
9. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW, 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 1104-1107. (Pubitemid 32299375)
10. Kumar V, Kesari S, Kumar AJ, Dinesh DS, Ranjan A, Prasad M, Sinha NK, Kumar R, Das P, 2009. Vector density and the control of kala-azar in Bihar, India. Mem Inst Oswaldo Cruz 104: 1019-1022.
11. Kumar V, Kesari S, Dinesh DS, Tiwari AK, Kumar AJ, Kumar R, Singh VP, Das P, 2009. A report on the indoor residual spraying (IRS) in the control of Phlebotomus argentipes, the vector of visceral leishmaniasis in Bihar (India): an initiative towards total elimination targeting 2015 (Series-1). J Vector Borne Dis 46: 225-229.
12. Joshi AB, Banjara MR, Pokhrel S, Jimba M, Singhasivanon P, Ashford RW, 2006. Elimination of visceral leishmaniasis in Nepal: pipe-dreams and possibilities. Kathmandu Univ Med J 4: 488-496. (Pubitemid 351507107)
13. Kedzierski L, 2010. Leishmaniasis vaccine: where are we today? J Glob Infect Dis 2: 177-185.
14. Nagill R, Kaur S, 2011. Vaccine candidates for leishmaniasis: a review. Int Immunopharmacol 11: 1464-1488.
15. Coler RN, Reed SG, 2005. Second-generation vaccines against leishmaniasis. Trends Parasitol 21: 244-249. (Pubitemid 40544642)
16. Velez ID, Gilchrist K, Martinez S, Ramirez-Pineda JR, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Piazza FM, 2009. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28: 329-337.
17. Olliaro P, Darley S, Laxminarayan R, Sundar S, 2009. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Trop Med Int Health 14: 918-925.
18. Open-Label Safety Study of Three-Antigen Leishmania Polyprotein with Adjuvant MPL-SE in Healthy Adults in India. Available at: http://www. ClinicalTrials.gov.Accessed June 5, 2010.
19. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG, 2007. Leish- 111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun 75: 4648-4654. (Pubitemid 47378126)
20. Lee BY, Burke DS, 2010. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine 28: 2806-2809.
21. World Health Organization, 2008. Global Health Observatory: World Health Organization. Geneva: WHO.
22. Bern C, Maguire JH, Alvar J, 2008. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2: e313.
23. Ahluwalia IB, Bern C, Wagatsuma Y, Costa C, Chowdhury R, Ali M, Amann J, Haque R, Breiman R, Maguire JH, 2004. Visceral leishmaniasis: consequences to women in a Bangladeshi community. J Womens Health (Larchmt) 13: 360-364.
24. Bern C, Joshi AB, Jha SN, Das ML, Hightower A, Thakur GD, Bista MB, 2000. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg 63: 184-188. (Pubitemid 32488357)
25. Salotra P, Singh R, 2006. Challenges in the diagnosis of post kala-azar dermal leishmaniasis. Indian J Med Res 123: 295-310. (Pubitemid 43905571)
26. Ministry of Finance Government of India, 2010. Economics Survey 2009-2010. Available at: http://indiabudget.nic.in/es2009-10/esmain.htm. Accessed June 3, 2010.
27. Singh VP, Ranjan A, Topno RK, Verma RB, Siddique NA, Ravidas VN, Kumar N, Pandey K, Das P, 2010. Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India. Am J Trop Med Hyg 82: 9-11.
28. Khalil EA, Zijlstra EE, Kager PA, El Hassan AM, 2002. Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan. Trop Med Int Health 7: 35-44. (Pubitemid 34131809)
29. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A, 1999. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 93: 319-323. (Pubitemid 29348832)
30. Piscopo TV, Mallia Azzopardi C, 2007. Leishmaniasis. Postgrad Med J 83: 649-657. (Pubitemid 44786872)
31. ter Horst R, Tefera T, Assefa G, Ebrahim AZ, Davidson RN, Ritmeijer K, 2009. Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia. Am J Trop Med Hyg 80: 929-934.
32. Ritmeijer K, Melaku Y, Mueller M, Kipngetich S, O'Keeffe C, Davidson RN, 2006. Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis. Am J Trop Med Hyg 74: 76-80. (Pubitemid 46768633)
33. Sundar S, Singh RK, Maurya R, Kumar B, Chhabra A, Singh V, Rai M, 2006. Serological diagnosis of Indian visceral leishmaniasis: direct agglutination test versus rK39 strip test. Trans R Soc Trop Med Hyg 100: 533-537.
34. Sundar S, Chatterjee M, 2006. Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res 123: 345-352. (Pubitemid 43905574)
35. Sundar S, Maurya R, Singh RK, Bharti K, Chakravarty J, Parekh A, Rai M, Kumar K, Murray HW, 2006. Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol 44: 251-253. (Pubitemid 43100614)
36. Roy P, Noad R, 2008. Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccin 4: 5-12. (Pubitemid 351785255)
37. Maltezou HC, 2010. Drug resistance in visceral leishmaniasis. J Biomed Biotechnol 2010: 617521.
38. Sarnoff R, Desai J, Desjeux P, Mittal A, Topno R, Siddiqui NA, Pandey A, Sur D, Das P, 2010. Visceral Leishmaniasis Supplement: The Economic Impact of Visceral Leishmaniasis on Rural Households in One Endemic District of Bihar, India. San Francisco, CA: Institute for One World Health.
39. Brenzel L, Wolfson LJ, Fox-Rushby J, Miller M, Halsey NA, 2006. Vaccine-preventable diseases. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, eds. Disease Control Priorities in Developing Countries. Second edition. Washington, DC: World Bank, Chap. 20.
40. Lee BY, Norman BA, Assi TM, Chen SI, Bailey RR, Rajgopal J, Brown ST, Wiringa AE, Burke DS, 2010. Single versus multidose vaccine vials: an economic computational model. Vaccine 28: 5292-5300.
41. PACIFIC Exchange Rate Service, 2010. Today's Exchange Rates: Thursday, June 3, 2010. Vancouver: Bank of Canada.
42. Shepard DS, 1999. Cost-effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. New York: Oxford University Press. JMent Health Policy Econ 2: 91-92.
43. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW, 2004. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 38: 377-383. (Pubitemid 38200114)
44. Singh UK, Prasad R, Jaiswal BP, Singh PK, Thakur CP, 2010. Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial. J Trop Pediatr 47: 749-751.
45. World Health Organization, 2004. Global Burden of Disease 2004 Update: Disability Weights for Diseases and Conditions. Geneva: World Health Organization.
46. World Health Organization, 2010. Health statistics and health information systems: Disability weights, discounting and age weighting of DALYs.Available at: http://www.who.int/healthinfo/ global-burden-disease/daly-disability-weight/ en/index.html. Accessed May 25, 2010.
47. Lopez AD, Ezzati M, Jamison DT, Murray CJL, 2006. Global Burden of Disease and Risk Factors. Washington, DC: The World Bank and Oxford University Press.
48. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504-512.
49. Croft SL, Sundar S, Fairlamb AH, 2006. Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126. (Pubitemid 43157649)
50. Picado A, Das ML, Kumar V, Kesari S, Dinesh DS, Roy L, Rijal S, Das P, Rowland M, Sundar S, Coosemans M, Boelaert M, Davies CR, 2010. Effect of village-wide use of long-lasting insecticidal nets on visceral leishmaniasis vectors in India and Nepal: a cluster randomized trial. PLoS Negl Trop Dis 4: e587.
51. Mathur P, Samantaray JC, Vajpayee M, Samanta P, 2006. Visceral leishmaniasis/human immunodeficiency virus co-infection in India: the focus of two epidemics. J Med Microbiol 55: 919-922. (Pubitemid 43974699)